Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

If Trump wants to improve Americans’ health, as he says, expanding coverage of weight-loss drugs should be a priority. With ...

We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

An SNRI (serotonin and norepinephrine reuptake inhibitor) is one of two major classes of medications used to treat clinical ...

At least 29 patent suits were filed in the District of New Jersey in November, reflecting a jump from the rate of 18 suits ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...